We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The U.S. Centers for Disease Control and Prevention (CDC) has published an analysis in the recent issue of its Morbidity and Mortality Weekly Report of Niger's national polio immunization campaign that was launched in November 2005.
The FDA has issued a warning to consumers not to buy or use prescription drugs from several Canadian websites that are reportedly selling counterfeit drugs.
Taiwan's stockpile of avian influenza antivirals has achieved the World Health Organization's (WHO) recommended size, according to the country's Department of Health.
Canadian biopharmaceutical company QLT Inc. on Tuesday denied a report that it received a buyout offer from a private equity group in February, after the report drove the company's shares up earlier in the day.
Protein Sciences Corporation (PSC) announced that it signed an agreement with UMN Pharma Inc., an entrepreneurial Japanese company (UMN), licensing FluBlOk, PSC's patented recombinant influenza vaccine, for the Japan market.
Cambridge Laboratories, a specialist pharmaceuticals company, has announced that its partner, OPi SA, has launched Xenazine 25mg (tetrabenazine) in France, following publication in the "Journal Officiel" of its reimbursement price that has been granted by the authorities.
AnorMED Inc. ("AnorMED" or the "Company")
announced that its Board of Directors has unanimously rejected an unsolicited approach from Genzyme Corporation ("Genzyme"), to purchase all of the issued and outstanding common shares of AnorMED for U.S. $8.55 per share in cash.
Ranbaxy Laboratories Limited (RLL) announced that a Norwegian court handed down a favorable decision for Ranbaxy in its case against Pfizer, involving two patents on atorvastatin in Norway.